Un-audited financial results of the Company for the half year ended on September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ganga Pharmaceuticals' board approved un-audited H1 FY26 results on November 7, 2025. Revenue from operations rose modestly by about 4% YoY to Rs. 136.65 lakhs, but total income slipped roughly 6% to Rs. 151.45 lakhs because other income halved. Profit before tax fell sharply by around 50% to Rs. 3.35 lakhs as total expenses ballooned to Rs. 188.10 lakhs (vs Rs. 153.70 lakhs). Net profit was nearly flat at Rs. 2.48 lakhs (vs Rs. 2.41 lakhs), with basic EPS of Rs. 0.04. The company raised Rs. 112.88 lakhs by converting 10.75 lakh of 17.75 lakh warrants, while forfeiting the remaining 7 lakh warrants for non-payment, lifting share capital to Rs. 591.15 lakhs. Operating cash flow remained deeply negative at about Rs. -92.42 lakhs. The auditor (Banka & Banka) issued a clean, unqualified limited review report.
Cost pressures compressed profitability despite stable revenue, and the continued operating cash burn is a red flag. Existing shareholders face per-share dilution from the enlarged capital base following the warrant conversion.